{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:35:22Z","timestamp":1785537322119,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Pediatr"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12519-024-00873-4","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T18:30:45Z","timestamp":1737657045000},"page":"62-72","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-7517","authenticated-orcid":false,"given":"Hugo","family":"Jourdain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Hoisnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Sbidian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Zureik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"11","key":"873_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","volume":"169","author":"MJ Rosen","year":"2015","unstructured":"Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169:1053.","journal-title":"JAMA Pediatr"},{"issue":"6","key":"873_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ibd.21152","volume":"16","author":"B Pigneur","year":"2010","unstructured":"Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohn\u02bcs disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953\u201361.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"873_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132:863\u201373.","journal-title":"Gastroenterology"},{"issue":"4","key":"873_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","volume":"10","author":"J Hyams","year":"2012","unstructured":"Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391-9.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"873_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/j.gastro.2012.04.046","volume":"143","author":"JS Hyams","year":"2012","unstructured":"Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn\u2019s disease in children. Gastroenterology. 2012;143:365-74.e2.","journal-title":"Gastroenterology"},{"issue":"3","key":"873_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MIB.0000000000001021","volume":"23","author":"WA Faubion","year":"2017","unstructured":"Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn\u02bcs Disease. Inflamm Bowel Dis. 2017;23:453\u201360.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"873_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","volume":"6","author":"NM Croft","year":"2021","unstructured":"Croft NM, Faubion WA, Kugathasan S, Kierkus J, Ruemmele FM, Shimizu T, et al. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2021;6:616\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"873_CR8","first-page":"796","volume":"52","author":"R Farr","year":"2022","unstructured":"Farr R, Karam L, Kitagawa S, Kellermayer R. Infliximab can be effective in pediatric patients with ulcerative colitis and primary failure of adalimumab. Ann Clin Lab Sci. 2022;52:796\u2013801.","journal-title":"Ann Clin Lab Sci"},{"key":"873_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/BTT.S183088","volume":"13","author":"P Alvisi","year":"2019","unstructured":"Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, et al. Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian society of pediatric gastroenterology, hepatology, and nutrition experience. BTT. 2019;13:13\u201321.","journal-title":"BTT"},{"issue":"12","key":"873_CR10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology\u2014drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157\u201367.","journal-title":"N Engl J Med"},{"issue":"4","key":"873_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/MPG.0000000000003683","volume":"76","author":"C Martinez-Vinson","year":"2023","unstructured":"Martinez-Vinson C, Lemoine A, Bouhnik Y, Braithwaite B, Fohlen-Weill A, Addison J. PERFUSE: non-interventional cohort study of patients receiving infliximab biosimilar sb2: results in pediatric patients. J Pediatr Gastroenterol Nutr. 2023;76:451\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"873_CR12","first-page":"1007","volume":"34","author":"V Dipasquale","year":"2022","unstructured":"Dipasquale V, Pellegrino S, Ventimiglia M, Cucinotta U, Citrano M, Graziano F, et al. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the sicilian network for inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2022;34:1007\u201314.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"873_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/archdischild-2017-313404","volume":"103","author":"L Richmond","year":"2018","unstructured":"Richmond L, Curtis L, Garrick V, Rogers P, Wilson M, Tayler R, et al. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2018;103:89\u201391.","journal-title":"Arch Dis Child"},{"issue":"6","key":"873_CR14","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/MPG.0000000000002091","volume":"67","author":"L Gervais","year":"2018","unstructured":"Gervais L, McLean LL, Wilson ML, Cameron C, Curtis L, Garrick V, et al. Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful. J pediatr gastroenterol nutr. 2018;67:745\u20138.","journal-title":"J pediatr gastroenterol nutr"},{"issue":"4","key":"873_CR15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/MPG.0000000000002011","volume":"67","author":"N Chanchlani","year":"2018","unstructured":"Chanchlani N, Mortier K, Williams LJ, Muhammed R, Auth MKH, Cosgrove M, et al. Use of infliximab biosimilar versus originator in a pediatric united kingdom inflammatory bowel disease induction cohort. J Pediatr Gastroenterol Nutr. 2018;67:513\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"873_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/apa.15026","volume":"109","author":"A Nikkonen","year":"2020","unstructured":"Nikkonen A, Kolho K. Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease. Acta Paediatr. 2020;109:836\u201341.","journal-title":"Acta Paediatr"},{"issue":"4","key":"873_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MPG.0000000000003890","volume":"77","author":"MG McClinchie","year":"2023","unstructured":"McClinchie MG, Lakhani A, Abdel-Rasoul M, McNicol M, Shkhkhalil AK, Boyle BB, et al. Similar growth outcomes in children with inflammatory bowel disease initiated on infliximab originator or biosimilar. J Pediatr Gastroenterol Nutr. 2023;77:499\u2013504.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"873_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/1744666X.2023.2284226","volume":"20","author":"V Dipasquale","year":"2024","unstructured":"Dipasquale V, Alibrandi A, Pellegrino S, Ramistella V, Romano C. Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population. Expert Rev Clin Immunol. 2024;20:237\u201344.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"873_CR19","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/MPG.0000000000001643","volume":"65","author":"J Sieczkowska-Golub","year":"2017","unstructured":"Sieczkowska-Golub J, Meglicka M, Plocek A, Banaszkiewicz A, Jarz\u0119bicka D, Toporowska-Kowalska E, et al. Induction therapy with biosimilar infliximab in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2017;65:285\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"8","key":"873_CR20","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1007\/s12325-021-01834-3","volume":"38","author":"JH Cheon","year":"2021","unstructured":"Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, et al. Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: pooled analysis of long-term safety and effectiveness. Adv Ther. 2021;38:4366\u201387.","journal-title":"Adv Ther"},{"issue":"2","key":"873_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/MPG.0000000000003838","volume":"77","author":"L Gianolio","year":"2023","unstructured":"Gianolio L, Armstrong K, Swann E, Shepherd R, Henderson P, Wilson DC, et al. Effectiveness of switching to subcutaneous infliximab in pediatric inflammatory bowel disease patients on intravenous maintenance therapy. J Pediatr Gastroenterol Nutr. 2023;77:235\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"873_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/PG9.0000000000000256","volume":"3","author":"A Hinshaw","year":"2022","unstructured":"Hinshaw A, Cares K, Thomas R, El-Baba M. Efficacy of infliximab biosimilar for maintenance therapy in pediatric inflammatory bowel disease following infliximab originator. JPGN Rep. 2022;3:e256.","journal-title":"JPGN Rep"},{"issue":"3","key":"873_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/FTD.0000000000000601","volume":"41","author":"K van Hoeve","year":"2019","unstructured":"van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, et al. Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory Bowel disease. Ther Drug Monit. 2019;41:317\u201324.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"873_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/ibd\/izx047","volume":"24","author":"B Kang","year":"2018","unstructured":"Kang B, Lee Y, Lee K, Choi YO, Choe YH. Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: a single-center prospective observational study. Inflamm Bowel Dis. 2018;24:607\u201316.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"873_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","volume":"10","author":"J Sieczkowska","year":"2016","unstructured":"Sieczkowska J, Jarz\u0119bicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary Observ ECCOJC. 2016;10:127\u201332.","journal-title":"Preliminary Observ ECCOJC"},{"key":"873_CR26","doi-asserted-by":"publisher","first-page":"175628481880124","DOI":"10.1177\/1756284818801244","volume":"11","author":"V Bergqvist","year":"2018","unstructured":"Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:175628481880124.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"873_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","volume":"2","author":"JL Lund","year":"2015","unstructured":"Lund JL, Richardson DB, St\u00fcrmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221\u20138.","journal-title":"Curr Epidemiol Rep"},{"key":"873_CR28","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique. 2017;65:S149\u201367.","journal-title":"Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"},{"issue":"3","key":"873_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jama.2022.21471","volume":"329","author":"N Roland","year":"2023","unstructured":"Roland N, Baricault B, Weill A, Bouillon K, Dray-Spira R, Duranteau L, et al. Association between doses of levonorgestrel intrauterine systems and subsequent use of psychotropic drugs in France. JAMA. 2023;329:257.","journal-title":"JAMA"},{"issue":"11","key":"873_CR30","doi-asserted-by":"publisher","first-page":"2342006","DOI":"10.1001\/jamanetworkopen.2023.42006","volume":"6","author":"E Kolla","year":"2023","unstructured":"Kolla E, Weill A, Zaidan M, De Martin E, Colin De Verdiere S, Semenzato L, et al. COVID-19 hospitalization in solid organ transplant recipients on immunosuppressive therapy. JAMA Netw Open. 2023;6:2342006.","journal-title":"JAMA Netw Open"},{"key":"873_CR31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207847","author":"S Le Vu","year":"2023","unstructured":"Le Vu S, Bertrand M, Botton J, Jabagi MJ, Drouin J, Semenzato L, et al. Risk of guillain-barr\u00e9 syndrome following COVID-19 vaccines: a nationwide self-controlled case series study. Neurology. 2023;101:e2094-102.","journal-title":"Neurology"},{"key":"873_CR32","first-page":"135245852312233","volume":"27","author":"M Swital","year":"2024","unstructured":"Swital M, Drouin J, Miranda S, Bakchine S, Botton J, Dray-Spira R. Use of multiple sclerosis disease-modifying therapies during pregnancy in France: nationwide study between 2010 and 2021. Mult Scler. 2024;27:13524585231223396.","journal-title":"Mult Scler"},{"issue":"1","key":"873_CR33","doi-asserted-by":"publisher","first-page":"19569","DOI":"10.1038\/s41598-022-24050-7","volume":"12","author":"H Jourdain","year":"2022","unstructured":"Jourdain H, Hoisnard L, Sbidian E, Zureik M. TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System. Sci Rep. 2022;12:19569.","journal-title":"Sci Rep"},{"issue":"1","key":"873_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2458-9-33","volume":"9","author":"G Rey","year":"2009","unstructured":"Rey G, Jougla E, Fouillet A, H\u00e9mon D. Ecological association between a deprivation index and mortality in France over the period 1997\u20132001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.","journal-title":"BMC Public Health"},{"issue":"2","key":"873_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7326\/M18-1512","volume":"170","author":"A Meyer","year":"2019","unstructured":"Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and safety of reference infliximab and biosimilar in Crohn Disease: a french equivalence study. Ann Intern Med. 2019;170:99\u2013107.","journal-title":"Ann Intern Med"},{"issue":"3","key":"873_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/apt.15323","volume":"50","author":"A Meyer","year":"2019","unstructured":"Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther. 2019;50:269\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"873_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100158","volume":"8","author":"L Semenzato","year":"2021","unstructured":"Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Health Eur. 2021;8:100158.","journal-title":"Lancet Regional Health Europe"},{"key":"873_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.21.20198853","author":"A Rachas","year":"2012","unstructured":"Rachas A, Gastaldi-M\u00e9nager C, Denis P, Lesuffleur T, Nicolas M, Pestel L, et al. Prevalences and healthcare expenditures related to 58 health conditions from 2012 to 2017 in France: diseases and healthcare expenditure mapping, a national population-based study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.09.21.20198853.","journal-title":"Public and Global Health"},{"key":"873_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00584-8","author":"H Jourdain","year":"2023","unstructured":"Jourdain H, Hoisnard L, Sbidian E, Zureik M. Severe hypersensitivity reactions at biosimilar versus originator rituximab treatment initiation, switch and over time: a cohort study on the french national health data system. BioDrugs. 2023;37:397-407.","journal-title":"BioDrugs"},{"key":"873_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2599","author":"L Penso","year":"2021","unstructured":"Penso L, Dray-Spira R, Weill A, Pina Vegas L, Zureik M, Sbidian E. Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol. 2021;157:1056-65.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"873_CR41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/bjd.16809","volume":"180","author":"E Sbidian","year":"2019","unstructured":"Sbidian E, Mezzarobba M, Weill A, Coste J, Rudant J. Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16 545 biologic-na\u00efve patients from the French National Health Insurance database (SNIIRAM). Br J Dermatol. 2019;180:86\u201393.","journal-title":"Br J Dermatol"},{"issue":"10","key":"873_CR42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158:1131.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"873_CR43","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the french health insurance database. JAMA Dermatol. 2022;158:513\u201322.","journal-title":"JAMA Dermatol"},{"issue":"13","key":"873_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.846151","volume":"17","author":"V Dipasquale","year":"2022","unstructured":"Dipasquale V, Cicala G, Spina E, Romano C. Biosimilars in pediatric inflammatory bowel diseases: a systematic review and real life-based evidence. Front Pharmacol. 2022;17:846151.","journal-title":"Front Pharmacol"}],"container-title":["World Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-024-00873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12519-024-00873-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12519-024-00873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T11:55:08Z","timestamp":1741348508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12519-024-00873-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["873"],"URL":"https:\/\/doi.org\/10.1007\/s12519-024-00873-4","relation":{},"ISSN":["1708-8569","1867-0687"],"issn-type":[{"value":"1708-8569","type":"print"},{"value":"1867-0687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Supplementary file was missing from this article and has now been uploaded.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are employees of the French National Health Insurance (CNAM), the French National Agency for Medicines and Health Products Safety (ANSM) and the Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP).\u00a0No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Given that data are anonymous, no informed consent to participate or publish was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EPI-PHARE has permanent regulatory access to the data via its constitutive bodies ANSM and CNAM, thus this present work did not require the approval from the French Data Protection Authority (CNIL). The study was registered on the study register of EPI-PHARE under the number T-2023\u201305-455.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}